United Therapeutics
UTHR
378 hedge funds and large institutions have $5.01B invested in United Therapeutics in 2019 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 129 increasing their positions, 132 reducing their positions, and 30 closing their positions.
63% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 30
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
9% more capital invested
Capital invested by funds: $4.6B → $5.01B (+$417M)
5% more funds holding
Funds holding: 360 → 378 (+18)
0.17% less ownership
Funds ownership: 98.19% → 98.02% (-0.17%)
2% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 132
42% less call options, than puts
Call options by funds: $32.6M | Put options by funds: $56.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$34.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$30.9M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$14.7M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$14.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$53.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$21.2M |
| 3 |
D.E. Shaw & Co
New York
|
-$18.9M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$15.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.6M |
UTHR Hedge Fund Activity: Q1 2019 in Review
378 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2019, worth a combined $5.01B — up 9.1% from $4.6B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new UTHR positions and 30 closed out — a net gain of 19 holders — while 129 added to existing stakes and 132 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $34.5M. The largest seller was Fidelity International, cutting an estimated $53.7M.
- 378 institutional investors held United Therapeutics (UTHR) as of Q1 2019, up from 360 in Q4 2018.
- Funds reported $5.01B of United Therapeutics stock for Q1 2019, up 9.1% quarter-over-quarter.
- 49 funds opened new United Therapeutics positions in Q1 2019 and 30 closed out, a net change of +19 holders.
- The largest United Therapeutics buyer in Q1 2019 was Arrowstreet Capital, an estimated $34.5M added.
- The largest United Therapeutics seller in Q1 2019 was Fidelity International, an estimated $53.7M sold.
Based on aggregated 13F filings for Q1 2019.